Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugsNovo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as…